Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $111.69, with 6.54 million shares of worth about $730.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.04% during that period and on December 11, 2024 the price saw a gain of about 2.29%. Currently the company’s common shares owned by public are about 3.34B shares, out of which, 3.34B shares are available for trading.
Stock saw a price change of 2.50% in past 5 days and over the past one month there was a price change of 2.38%. Year-to-date (YTD), NVO shares are showing a performance of 7.97% which increased to 15.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $94.73 but also hit the highest price of $148.15 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 5.12 million. The stock is currently trading 4.81% above its 20-day simple moving average (SMA20), while that difference is up 0.55% for SMA50 and it goes to -12.06% lower than SMA200.
Novo Nordisk ADR (NYSE: NVO) currently have 3.34B outstanding shares and institutions hold larger chunk of about 10.00% of that.
The stock has a current market capitalization of $372.87B and its 3Y-monthly beta is at 0.40. PE ratio of stock for trailing 12 months is 36.22, while it has posted earnings per share of $3.08 in the same period. Its PEG reads 3.29 and has Quick Ratio of 0.75 while making debt-to-equity ratio of 0.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 1.77% while standing at 1.75% over the month.
Stock’s fiscal year EPS is expected to rise by 20.09% while it is estimated to increase by 24.40% in next year. EPS is likely to shrink at an annualized rate of 11.00% for next 5-years, compared to annual growth of 16.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on May 30, 2024 offering a Buy rating for the stock and assigned a target price of $156 to it. Coverage by BMO Capital Markets stated Novo Nordisk ADR (NVO) stock as an Outperform in their note to investors on April 12, 2024, suggesting a price target of $163 for the stock. Stock get an Overweight rating from Cantor Fitzgerald on December 01, 2023.
